Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ALD
|
|||
| Former ID |
DNCL002850
|
|||
| Drug Name |
Empagliflozin
|
|||
| Synonyms |
864070-44-0; JARDIANCE; BI 10773; UNII-HDC1R2M35U; Empagliflozin (BI 10773); BI-10773; BI10773; HDC1R2M35U; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; AK160980; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10; ICD-9: 250] | Approved | [1], [2] | |
| Company |
Boehringer Ingelheim Pharmaceuticals; Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27ClO7
|
|||
| Canonical SMILES |
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
|
|||
| InChI |
1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
|
|||
| InChIKey |
OBWASQILIWPZMG-QZMOQZSNSA-N
|
|||
| CAS Number |
CAS 864070-44-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
17390987, 23917761, 35020536, 80625411, 135267035, 136350032, 137759455, 160647541, 160671533, 162201844, 163620871, 170500874, 172232552, 178101464, 186021010, 189024748, 198945623, 206246269, 211535427, 223447440, 223471392, 223602217, 223701070, 227166637, 241383513, 242077478, 245606277, 249737155, 249865857, 251963060, 252067199, 252159682, 252215347
|
|||
| ChEBI ID |
CHEBI:82720
|
|||
| ADReCS Drug ID | BADD_D00765 | |||
| SuperDrug ATC ID |
A10BX12
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Modulator | [2] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4754). | |||
| REF 2 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.